+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neurological Biomarkers Market Research Report by Type, Application, End-user, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 123 Pages
  • October 2022
  • Region: United States
  • 360iResearch™
  • ID: 5455816
UP TO OFF until Dec 31st 2022
The United States Neurological Biomarkers Market size was estimated at USD 1,411.27 million in 2021, USD 1,688.14 million in 2022, and is projected to grow at a CAGR of 15.87% to reach USD 3,416.32 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Neurological Biomarkers to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Genomic, Imaging, Metabolomic, and Proteomic.
  • Based on Application, the market was studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease.
  • Based on End-user, the market was studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies This research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neurological Biomarkers market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neurological Biomarkers Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Neurological Biomarkers Market, including AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Inc., Athena Diagnostics Inc, Banyan Biomarkers, Inc., Bio-Rad Laboratories, Inc., Diagenic ASA, Imagilys, Invicro. LLC., IXICO plc, Myriad RBM, Proteome Sciences Plc, Psynova Neurotech, Qiagen N.V., Quanterix Corporation, Sigma-Aldrich, Inc, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Neurological Biomarkers Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Neurological Biomarkers Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Neurological Biomarkers Market?
4. What is the competitive strategic window for opportunities in the United States Neurological Biomarkers Market?
5. What are the technology trends and regulatory frameworks in the United States Neurological Biomarkers Market?
6. What is the market share of the leading vendors in the United States Neurological Biomarkers Market?
7. What modes and strategic moves are considered suitable for entering the United States Neurological Biomarkers Market?
Frequently Asked Questions about the U.S. Neurological Biomarkers Market

What is the estimated value of the U.S. Neurological Biomarkers Market?

The U.S. Neurological Biomarkers Market was estimated to be valued at $1411.27 Million in 2021.

What is the growth rate of the U.S. Neurological Biomarkers Market?

The growth rate of the U.S. Neurological Biomarkers Market is 15.8%, with an estimated value of $3416.32 Million by 2027.

What is the forecasted size of the U.S. Neurological Biomarkers Market?

The U.S. Neurological Biomarkers Market is estimated to be worth $3416.32 Million by 2027.

Who are the key companies in the U.S. Neurological Biomarkers Market?

Key companies in the U.S. Neurological Biomarkers Market include AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Inc., Athena Diagnostics Inc, Banyan Biomarkers, Inc., Bio, Rad Laboratories, Inc. and Imagilys.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Neurological Biomarkers Market, by Type
6.1. Introduction
6.2. Genomic
6.3. Imaging
6.4. Metabolomic
6.5. Proteomic
7. Neurological Biomarkers Market, by Application
7.1. Introduction
7.2. Alzheimer’s Disease
7.3. Autism Spectrum Disorders
7.4. Multiple Sclerosis
7.5. Parkinson’s Disease
8. Neurological Biomarkers Market, by End-user
8.1. Introduction
8.2. Hospital Laboratories
8.3. Independent Clinical Diagnostic Centers
8.4. Research Organizations
9. California Neurological Biomarkers Market
9.1. Introduction
10. Florida Neurological Biomarkers Market
10.1. Introduction
11. Illinois Neurological Biomarkers Market
11.1. Introduction
12. New York Neurological Biomarkers Market
12.1. Introduction
13. Ohio Neurological Biomarkers Market
13.1. Introduction
14. Pennsylvania Neurological Biomarkers Market
14.1. Introduction
15. Texas Neurological Biomarkers Market
15.1. Introduction
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. AbaStar MDx, Inc.
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Abbott Laboratories
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. Acumen Pharmaceuticals
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Alseres Pharmaceuticals, Inc.
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Athena Diagnostics Inc
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Banyan Biomarkers, Inc.
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. Bio-Rad Laboratories, Inc.
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. Diagenic ASA
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. Imagilys
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. Invicro. LLC.
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. IXICO plc
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Myriad RBM
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. Proteome Sciences Plc
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
17.14. Psynova Neurotech
17.14.1. Business Overview
17.14.2. Key Executives
17.14.3. Product & Services
17.15. Qiagen N.V.
17.15.1. Business Overview
17.15.2. Key Executives
17.15.3. Product & Services
17.16. Quanterix Corporation
17.16.1. Business Overview
17.16.2. Key Executives
17.16.3. Product & Services
17.17. Sigma-Aldrich, Inc
17.17.1. Business Overview
17.17.2. Key Executives
17.17.3. Product & Services
17.18. Thermo Fisher Scientific Inc.
17.18.1. Business Overview
17.18.2. Key Executives
17.18.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
FIGURE 8. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2027
FIGURE 11. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 16. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 18. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 23. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USER, 2027
FIGURE 25. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2027 (USD MILLION)
FIGURE 26. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, 2018-2027 (USD MILLION)
FIGURE 27. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2027 (USD MILLION)
FIGURE 28. CALIFORNIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 29. FLORIDA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 30. ILLINOIS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 31. NEW YORK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. OHIO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 33. PENNSYLVANIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 34. TEXAS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 35. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 36. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 37. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, 2018-2027 (USD MILLION)
TABLE 27. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 28. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2027 (USD MILLION)
TABLE 29. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY STATE, 2018-2027 (USD MILLION)
TABLE 30. CALIFORNIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 31. CALIFORNIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 32. CALIFORNIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 33. CALIFORNIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 34. FLORIDA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 35. FLORIDA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 36. FLORIDA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 37. FLORIDA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 38. ILLINOIS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. ILLINOIS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 40. ILLINOIS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 41. ILLINOIS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 42. NEW YORK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. NEW YORK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44. NEW YORK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 45. NEW YORK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 46. OHIO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 47. OHIO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 48. OHIO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 49. OHIO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 50. PENNSYLVANIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 51. PENNSYLVANIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 52. PENNSYLVANIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 53. PENNSYLVANIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 54. TEXAS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 55. TEXAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 56. TEXAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 57. TEXAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 58. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 59. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 60. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 61. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 62. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 63. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET MERGER & ACQUISITION
TABLE 64. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 65. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 66. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET INVESTMENT & FUNDING
TABLE 67. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 68. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbaStar MDx, Inc.
  • Abbott Laboratories
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals, Inc.
  • Athena Diagnostics Inc
  • Banyan Biomarkers, Inc.
  • Bio-Rad Laboratories, Inc.
  • Diagenic ASA
  • Imagilys
  • Invicro. LLC.
  • IXICO plc
  • Myriad RBM
  • Proteome Sciences Plc
  • Psynova Neurotech
  • Qiagen N.V.
  • Quanterix Corporation
  • Sigma-Aldrich, Inc
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...